Amgen company profile

AMGN · NASDAQ · USD

Compare Amgen
$465.67Change from previous close: −0.30%Absolute change: −$1.39

Close · November 13, 2026

Company profile

Amgen has 31,500 employees and is headquartered in Thousand Oaks, United States.

Amgen's largest business is human therapeutics, which it discovers, develops, manufactures and delivers worldwide. Its principal products cover inflammatory diseases such as rheumatoid arthritis and psoriasis, bone disorders including osteoporosis, cardiovascular risk reduction, and cancers such as multiple myeloma and colorectal cancer, with brands including Enbrel, Otezla, Prolia, Repatha and KYPROLIS. The company sells to physicians and their clinics, dialysis centers, hospitals and pharmacies, largely through pharmaceutical wholesale distributors, and it works with partners such as AstraZeneca, UCB and BeiGene on several of its products.

In the fiscal year ended December 2025, Amgen reported revenue of 36.8 billion US dollars, up 10.0% from the previous year, and net income of 7.7 billion US dollars. The US accounted for 71.9% of revenue and non-US markets for 28.1%. The company had 31,500 employees and is headquartered in Thousand Oaks, California, where it was incorporated in 1980.

Company facts

Industry
Drug Manufacturers - General
Headquarters
One Amgen Center Drive, 91320-1799, Thousand Oaks
Employees
31,500
Chief executive
Robert Bradway
Founded
1980
Fiscal year
January - December
Listing
AMGN · NASDAQ
Currency
USD
ISIN
US0311621009
Website
amgen.com

Amgen and its competitors

The most similar companies by business and size

CompanyCountryMarket capEmployeesOperating marginP/E (trailing 12 months)
AmgenAMGNUnited States$251.89B31,50034.1%27.0
Gilead SciencesGILDUnited States$208.48B17,00038.2%—
Merck & Co.MRKUnited States$364.26B73,00035.2%147.8
PfizerPFEUnited States$164.67B75,00029.1%41.3
Bristol-Myers SquibbBMYUnited States$129.66B32,50032.4%14.1
AbbVieABBVUnited States$521.5B57,00036.6%50.6

Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.

Compare Amgen with its competitors